A trial of CAR-T cells containing a third-generation CAR construct with both CD28 and CD137 co-stimulatory signals is still recruiting patients with relapsed/refractory ALL (NCT02186860). This evidence concerns the gene TNFRSF9 and acute lymphoblastic leukemia.